Glenmark
Glenmark Life Sciences IPO पहले ही दिन हुआ ओवरसब्सक्राइब, 6 अगस्त को हो सकती है लिस्टिंग
ग्लेनमार्क की सब्सिडियरी ग्लेनमार्क लाइफ साइंसेज के रिटेल निवेशकों के लिए रिजर्व शे
Glenmark Life Sciences का IPO आज से खुला, एक्सपर्ट से जानिए इसमें पैसे लगाएं या नहीं
Glenmark Life Sciences IPO: ग्लेनमार्क लाइफ साइंसेज का 1514 करोड़ रुपये का आईपीओ मंगलवार 27 जुलाई को खुला ह
Glenmark Life Sciences IPO opens July 27, IPO size reduced; plans to sell now 63 lakh shares via OFS
Glenmark Life Sciences', a subsidiary of Glenmark Pharmaceuticals, IPO will open for subscription next week on 27 July and close on 29 July 2021.
Glenmark Q4 net profit up 6 pc at Rs 233.87 cr
The company has in place strategic levers to grow its businesses sustainably, with a focus on strengthening its balance sheet, he added.
Glenmark launches offer to raise up to $200 million
Glenmark Pharmaceuticals today launched an offer on the Singapore Stock Exchange to raise up to USD 200 million (over Rs 1,340 crore) through issue of securities.
Glenmark launches ‘Digihaler’ for asthma and COPD medication
The next-gen digital inhaler provides accurate digital dose counter along with low dose warning indicator to track patience adherence Glenmark Pharmaceuticals has announced launch of ‘Digihaler,’ a Digital Dose In
IPA announces new office bearers
The IPA, initially formed by eight national companies in November 1999 has now 20 research-based national pharmaceutical companies in its fold
Delhi HC questions govt over urgency to ban over 300 FDC drugs
Additional Solicitor General was responding to the contentions of pharma companies like Pfizer, Glenmark, Procter and Gamble and Cipla
Glenmark gets final FDA nod for migraine headache relief drug
Glenmark Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the American market.
Top 5 stocks that remained in news today: Quick Heal, Glenmark Pharma and more
Quick Heal Technologies made a weak stock market debut on Thursday. Quick Heal share price closed 20.73 per cent down at Rs 254 against the issue price of Rs 321.
Glenmark starts studies on new drug aimed at cancer treatment
The novel clinical development candidate, GBR1342 is an antibody based on the company's proprietary BEAT platform, Glenmark Pharmaceuticals said in a regulatory filing.
Glenmark shares gain on USFDA’s tentative nod for Sanofi’s generic Multaq
Glenmark Pharmaceuticals shares gained over 2 per cent in morning trade on Wednesday after the company received a tentative nod from the US health regulator for generic version of Sanofi-Aventis' cardiac drug Multaq.
Glenmark gets tentative FDA nod for Sanofi’s generic Multaq
However, the company cannot sell the product in the US as it is involved in a patent litigation with Sanofi in the district court of Delaware.
Glenmark gets USFDA final nod for anti-bacterial drug
Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the US Food & Drug Administration (USFDA) for the Linezolid tablets, 600 mg.
Glenmark settles patent litigation over anti-depressant drug
Glenmark and its US arm Glenmark Pharmaceuticals Inc have entered into a settlement agreement with Forest Laboratories LLC, Forest Laboratories Holdings Ltd and Royalty Pharma Collection Trust to settle the litigation.
Glenmark gets tentative USFDA nod for Lacosamide tablets
Glenmark Pharmaceuticals today said it has received tentative approval from the US health regulator for its Lacosamide tablets.
Glenmark’s bi-apecific antibody – GBR 1302 to enter Phase I trials
Glenmark expects to obtain approval for the initiation of clinical studies with GBR1302 during this financial year Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, announces the com
Glenmark stocks rise to record; USFDA gives nod for oral contraceptive drug
Shares of Glenmark Pharmaceuticals rose 5.9 per cent intraday to mark its record high as it received final approval from the the United States Food & Drug Administration...
Glenmark receives USFDA nod for oral contraceptive drug
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator to sell oral contraceptive -- drospirenone and ethinyl estradiol tablets -- in the US market.
Outperform on Glenmark; one of our top mid-cap picks: IDFC Securities
Glenmark’s consolidated revenues grew by 11% yoy to Rs 1,660 crore (in line), led by LatAm (+86%) and India (+19%).
US court rejects Glenmark’s patent plea for Finacea
Drug firm Glenmark's generic skin care drug that was under patent litigation infinges patent of Bayer, a US court has ruled.
Glenmark Pharmaceuticals launches ‘affordable’ Type 2 diabetes drug
Glenmark Pharmaceuticals on Wednesday launched ‘affordable’ gliptin for treatment of Type-2 Diabetes mellitus.
Glenmark obtains ANDA approval for levonorgestrel and ethinyl estradiol tabs
Glenmark Pharmaceuticals Inc., US (Glenmark) has been granted final approval by the US Food and Drug Administration for the extended-cycle oral contraceptive, levonorgestrel/ethinyl estradiol tablets USP, 0.15 mg/0.03 mg, the
Glenmark Pharma may surprise on upside despite headwinds
We note three key positives for the stock: 1) Glenmark Pharma (GNP) has stepped up filings in the US, and as of March 2015, it had 76 pending ANDAs with brand sales of $30 billion.
Temasek unit to invest Rs 945 cr in Glenmark
Pharmaceutical major Glenmark on Friday announced the issue of preferential equity shares worth Rs 945 crore to Temasek’s...
